Cargando…

Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study

INTRODUCTION: Effective blood glucose control remains a constant problem in patients with type 2 diabetes (T2D), even if they are being properly treated with one or more currently available drugs. The present study was designed as a 3-year retrospective observational study to determine whether the u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ku, Eu Jeong, Oh, Tae Keun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363093/ https://www.ncbi.nlm.nih.gov/pubmed/37369826 http://dx.doi.org/10.1007/s13300-023-01437-x

Ejemplares similares

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
por: Danne, Thomas, et al.
Publicado: (2015)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Quadruple H therapy for vasospasm
por: Walid, M. Sami, et al.
Publicado: (2009)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
por: Hui, Elaine, et al.
Publicado: (2013)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Zhou, Wenchuan, et al.
Publicado: (2019)

Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Psychometric Analysis Regarding the Barriers to Providing Effective Insulin Treatment in Type 2 Diabetic Patients
por: Ku, Eu Jeong, et al.
Publicado: (2020)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
por: McCrimmon, Rory J., et al.
Publicado: (2022)

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
por: Malkin, Samuel J. P., et al.
Publicado: (2022)

Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure
por: Fakheri, Hafez, et al.
Publicado: (2016)

Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
por: Lim, Hyun, et al.
Publicado: (2018)

Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy
por: Kim, Min Soo, et al.
Publicado: (2013)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Genetic variation in TCF7L2 rs7903146 correlating with peripheral arterial disease in long-standing type 2 diabetes
por: Ku, Eu Jeong, et al.
Publicado: (2019)

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
por: Rosenstock, J., et al.
Publicado: (2015)

Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment
por: Schroeder, Emily B., et al.
Publicado: (2021)

Concepts and clinical use of ultra-long basal insulin
por: Eliaschewitz, Freddy Goldberg, et al.
Publicado: (2016)

Can Fasting Glucose Levels or Post-Breakfast Glucose Fluctuations Predict the Occurrence of Nocturnal Asymptomatic Hypoglycemia in Type 1 Diabetic Patients Receiving Basal-Bolus Insulin Therapy with Long-Acting Insulin?
por: Mitsuishi, Sumie, et al.
Publicado: (2015)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
por: Papaetis, Georgios S.
Publicado: (2021)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study
por: Cho, Yun Kyung, et al.
Publicado: (2020)

Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study
por: Ku, Eu Jeong, et al.
Publicado: (2023)

Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Which is the best choice for Helicobacter pylori eradication? Dual therapy or quadruple therapy?
por: Bacaksız, Elif Gram, et al.
Publicado: (2022)

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
por: Alsofiani, Wafa A, et al.
Publicado: (2022)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
por: Home, Philip D.
Publicado: (2013)

Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China
por: Chen, Minyuan, et al.
Publicado: (2022)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Synchronous Quadruple Lung Cancer Treated Curatively by Photodynamic Therapy
por: Saito, Makoto, et al.
Publicado: (1996)

Response to: Treatment Prolongation or Quadruple Therapy:- Individualization by Geographical Region
por: Alsohaibani, Fahad, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dc2hfjra7p83a2qspea7tlo9n6